Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 9/20 | 0.68 |
| ▸ | BRD4 | O60885 | 6/20 | 0.68 |
| ▸ | EP300 | Q09472 | 3/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916250 | 0.89 | BRD4 (0.54) | CREBBPBRD4EP300CYP11B2EGLN1 | |
| SCHEMBL4927248 | 0.85 | CREBBP (0.93) | CREBBPBRD4EP300 | |
| SCHEMBL14144732 | 0.85 | CREBBP (0.67) | CREBBPBRD4EP300 | |
| SCHEMBL4923915 | 0.84 | BRD4 (0.49) | CREBBPBRD4EP300CYP11B2EGLN1 | |
| SCHEMBL4925458 | 0.84 | CREBBP (0.71) | CREBBPBRD4EP300 | |
| SCHEMBL4923889 | 0.83 | CNR2 (0.46) | CREBBPBRD4EGLN1 | |
| SCHEMBL4923871 | 0.82 | CREBBP (0.64) | CREBBPBRD4 | |
| SCHEMBL4918956 | 0.81 | CREBBP (0.62) | CREBBPBRD4 | |
| SCHEMBL4923434 | 0.79 | RIPK3 (0.44) | CREBBPBRD4CYP11B2EGLN1CYP11B1 | |
| SCHEMBL4736108 | 0.74 | BRD4 (0.73) | CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079316-A1 | TETRAHYDROQUINOLINONES, TETRAHYDRONAPHTHYRIDONES AND DERIVATIVES THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CNR1, CNR2, TRPV1 | CREBBP 3109/4885BRD4 407/4885EP300 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.